Elevating Early Detection: Transforming CRM Care Through Connected, System-Wide Action

Welcome back to another AJMC Insights series. In this episode titled, ‘Addressing the Challenges of Undiagnosed Chronic Kidney Disease’, Manisha Jhamb led the conversation

Rising urine albumin signals hidden kidney and heart risk; learn why earlier UACR/eGFR screening and new therapies can change CKD outcomes.

Welcome back to another AJMC Insights series. In this episode titled, 'The Financial and Clinical Cost of Delayed MASH Detection and Fragmented Care', Dr. Jaideep Behari led the conversation about the following questions: The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

In this episode, 'System-Level Barriers and Evidence Gaps in the Adoption of Emerging MASH Therapies,' the expert hepatologist explored the following questions: What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

The panelist explored the following critical questions: What systems-level strategies can improve coverage readiness for new metabolic dysfunction-associated steatohepatitis (MASH) treatments? What system-wide transformations are necessary to sustain scalable, multidisciplinary MASH care? What barriers exist to adopting emerging metabolic dysfunction-associated steatohepatitis (MASH) therapies at the system level, and how can they be overcome? What clinical and economic evidence is needed for formulary adoption of new therapies? The estimated financial burden of metabolic dysfunction-associated steatohepatitis (MASH) is considerable. How does delayed detection and intervention impact the overall cost of MASH care? What financial and clinical benefits arise from implementing early detection programs for MASH? How does fragmentation within the MASH ecosystem affect value-based care outcomes? How can population health efforts optimize these outcomes?

Rising urine albumin signals higher heart and kidney risk; learn how better screening, EHR prompts, and new therapies can transform CKD care.

How awareness, screening, and team-based care help catch chronic kidney disease early and cut heart risk with new protective medicines.

Uncover hidden CKD in type 2 diabetes: boost UACR screening, close diagnosis-to-treatment gaps, and navigate modern obesity therapies.

Learn why CKD often goes undiagnosed in type 2 diabetes and how UACR screening plus obesity therapies can cut cardiovascular risk.

How combined therapies and proactive, team-based CRM care cut costs, streamline meds, and improve heart, kidney, and metabolic outcomes.

How health systems break silos with multidisciplinary, patient-centered teams to improve CRM outcomes through coordinated, holistic care.